Macquarie has reiterated its “outperform” rating on Divi’s Laboratories, Cohance, Syngene, and Blue Jet Healthcare. Previous Post Yes Bank shares jump 8%, set for best weekly performance since May Next Post Gold rates steady after recent rally: Key drivers and price trends Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email, and website in this browser for the next time I comment.Post Comment